Speeding up COVID-19 PCR-test diagnostics
SARS-CoV-2 RNA extraction in just 2 minutes
BioEcho’s patent-pending technology is based on a single-step nucleic acid extraction method and differs from the products available on the market, which are established on a silica column that follows the bind-wash-elute principle. The cutting-edge BioEcho technology increases the throughput by reducing the time for viral genetic material extraction procedure to 2 minutes following sample preparation. Speeding up this step more than 20-fold over other extraction technologies leads to thousands of tests on COVID-19 easily achievable per day.
Agile solutions for molecular diagnostics
BioEcho’s pioneering product, EchoLUTION for viral RNA and DNA extraction 48-well or 96-well kit, has been validated by multiple diagnostic laboratories for SARS-CoV-2 detection from nasopharyngeal samples. All could significantly increase their test-throughput up to many thousands per day. BioEcho’s viral nucleic acids extraction products already cover almost 12% COVID-19 PCR tests performed in Germany and estimated 50% in Austria. Currently, BioEcho is working towards implementing precise, reproducible, and rapid, automated solutions, as well as developing new technologies for the detection of numerous pathogens.
BioEcho Life Sciences is a young and innovative company active in the field of Genomic Sample Preparation – the isolation and processing of DNA and RNA. Founded by a team of former Qiagen executives, BioEcho uses their know how to overcome the limitations of common methods in molecular biology and to establish sustainable processes. Their technological solutions were unthinkable until recently. Core technologies include dramatically simplified isolation procedures for nucleic acids in a single step, which form the basis of BioEcho’s portfolio of kits for purification and processing of DNA and RNA. Applying their single-step technologies, BioEcho Life Sciences paves the way for future nucleic acid analyses as well as novel approaches in genomic research and molecular diagnostics.
BioEcho Life Sciences GmbH
Nattermannallee 1
50829 Köln
Telefon: +49 221 998897 0
http://www.bioecho.de/
Product Manager
Telefon: +49 221 998897 18
E-Mail: maria.salazar.rondon@bioecho.de
CBO
Telefon: +49 221 998897 11
E-Mail: frank.schaefer@bioecho.de
